Literature DB >> 26823707

UCH-LI acts as a novel prognostic biomarker in gastric cardiac adenocarcinoma.

Honghong Yang1, Chunhong Zhang2, Shan Fang3, Rongying Ou4, Wenfeng Li5, Yunsheng Xu1.   

Abstract

Gastric cardiac adenocarcinoma (GCA) accounts for a majority of gastric cancer population and harbors unfavorable outcome. Ubiquitin C-terminal hydrolase L1 (UCH-L1) belongs to the deubiquitinating enzyme family, which could regulate cell growth in human cancers. In the present study, expression of UCH-L1 was evaluated in 196 GCAs by immunohistochemistry using tissue microarray and its function on gastric cancer cells was measured. UCH-L1 expression was increased in GCA specimens, compared with their normal tissues and UCH-L1 overexpression is tightly correlated with tumor size and overall TNM stage. Log-rank analysis showed that UCH-L1 positive is reversely associated with cumulative survival (P<0.001). Multivariate Cox regression model showed that UCH-L1 overexpression is a remarkably negative predictor in GCA prognosis (Hazard Ratio=0.53, P<0.01), along with advanced TNM stage that is a known negative factor in gastric cancers (Hazard Ratio=0.33, P<0.05). Silencing of UCH-L1 reduced the ability of cell proliferation, colony formation, migration and invasion of gastric cancer cells. Our findings suggest that UCH-L1 is a promising prognostic biomarker for GCAs and might play an important role in the carcinogenesis of gastric cancer.

Entities:  

Keywords:  Gastric cardiac adenocarcinoma; UCH-L1; biomarker; survival

Mesh:

Substances:

Year:  2015        PMID: 26823707      PMCID: PMC4713493     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

1.  Revised guidelines signal that gene expression profiles are coming of age.

Authors:  Steve Benowitz
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

2.  Detection and clinical significance of lymph node micrometastasis in gastric cardia adenocarcinoma.

Authors:  Y Ru; L Zhang; Q Chen; S G Gao; G P Wang; Z F Qu; T Y Shan; N Qian; X S Feng
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

3.  A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

Authors:  Christopher J Peters; Jonathan R E Rees; Richard H Hardwick; James S Hardwick; Sarah L Vowler; Chin-Ann J Ong; Chunsheng Zhang; Vicki Save; Maria O'Donovan; Doris Rassl; Derek Alderson; Carlos Caldas; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

4.  Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma.

Authors:  S L Zhou; J W Ku; Z M Fan; W B Yue; F Du; Y F Zhou; Y L Liu; Y Li; S Tang; Y L Hu; X P Hu; Z C Hou; J Liu; Y Liu; X S Feng; L D Wang
Journal:  Dis Esophagus       Date:  2014-03-10       Impact factor: 3.429

5.  Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor.

Authors:  Sajjad Hussain; Andrew L Feldman; Chittaranjan Das; Steven C Ziesmer; Stephen M Ansell; Paul J Galardy
Journal:  Mol Cell Biol       Date:  2013-01-07       Impact factor: 4.272

6.  Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.

Authors:  Tomohiro Kabuta; Takeshi Mitsui; Masaki Takahashi; Yuuki Fujiwara; Chihana Kabuta; Chiho Konya; Yukihiro Tsuchiya; Yusuke Hatanaka; Kenko Uchida; Hirohiko Hohjoh; Keiji Wada
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

7.  Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach.

Authors:  Hiroaki Saito; Youji Fukumoto; Tomohiro Osaki; Kenji Fukuda; Shigeru Tatebe; Shunichi Tsujitani; Masahide Ikeguchi
Journal:  World J Surg       Date:  2006-10       Impact factor: 3.352

8.  Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.

Authors:  Guanzhen Yu; Jiejun Wang; Ying Chen; Xi Wang; Jun Pan; Gang Li; Zhiliang Jia; Qiang Li; James C Yao; Keping Xie
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

9.  Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience.

Authors:  A Dechaphunkul; K Mulder; F El-Gehani; S Ghosh; J Deschenes; J Spratlin
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

10.  Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.

Authors:  Yichin Liu; Hilal A Lashuel; Sungwoon Choi; Xuechao Xing; April Case; Jake Ni; Li-An Yeh; Gregory D Cuny; Ross L Stein; Peter T Lansbury
Journal:  Chem Biol       Date:  2003-09
View more
  3 in total

1.  UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.

Authors:  Yanhong Luo; Jianfeng He; Chunlin Yang; Matthew Orange; Xingcong Ren; Nick Blair; Tao Tan; Jin-Ming Yang; Hua Zhu
Journal:  J Cell Biochem       Date:  2017-07-31       Impact factor: 4.429

2.  Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.

Authors:  Basile Tessier-Cloutier; Dawn R Cochrane; Anthony N Karnezis; Shane Colborne; Jamie Magrill; Aline Talhouk; Jonathan Zhang; Samuel Leung; Christopher S Hughes; Anna Piskorz; Angela S Cheng; Kendall Greening; Andreas du Bois; Jacobus Pfisterer; Robert A Soslow; Stefan Kommoss; James D Brenton; Gregg B Morin; C Blake Gilks; David G Huntsman; Friedrich Kommoss
Journal:  Hum Pathol       Date:  2020-04-29       Impact factor: 3.466

Review 3.  Clinical Applications of Extracellular Vesicles in the Diagnosis and Treatment of Traumatic Brain Injury.

Authors:  Kryshawna Beard; David F Meaney; David Issadore
Journal:  J Neurotrauma       Date:  2020-06-02       Impact factor: 4.869

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.